Abstract. Human MDM2 (murine double minute 2), amplified and overexpressed frequently in most of tumors and cancers, directly interacts with and inhibits the tumor suppressor protein p53. Understanding the regulation mechanism of MDM2 has recently been highlighted because of its roles in the regulation of p53 in cancer biology. MDM2 contains three domains. The N-terminal region interacts with p53 and downregulates its activity. The RING finger domain has ubiquitin ligase activity that can mediate p53 ubiquitination and degradation. Many studies showed that the central region of MDM2 is critical for p53 activation and tumor suppression. To date, more than twenty proteins have been shown to bind to this central region and further to be involved in the regulations of p53. However, how these interacting proteins precisely interact with MDM2 remains to be elucidated. We solved the first structure of the human MDM2-RPL11 complex. Both the acidic domain and C4 zinc finger of MDM2 are essential for RPL11 binding. Moreover, another unexpectedly zinc finger that forms inter-molecularly within the complex. A small molecule imidazole was found to be chelated in this zinc finger, which might be a promising start of drug design. These structural and functional information combining with earlier studies of MDM2 with other interacting proteins establish MDM2 as a novel class of therapeutic targets in human diseases such as cancers, yield insights into the MDM2-p53 surveillance pathway and could also yield useful anticancer strategies.
. Functional domains of MDM2 and the regions that are bound by various proteins.
MDM2 is the best characterized negative regulator of p53. MDM2 has gained much attention for its special functions in regulating p53. There are different factors controlling the MDM2-p53 signaling in response to different stresses, such as DNA damage, oncogenic activation, and ribosomal stress (Zhou et al., 2012) . DNA damage mediated by ATM/ATR kinases, oncogenic stresses by ARF induction and ribosomal stress through ribosomal proteins represent three major p53-activating pathways.
MDM2 encodes three domains: the N-terminal p53-binding region, the C-terminal RING finger domain, and the central region that includes an acidic region and a C4 zinc finger domain. The N-terminal region downregulates p53's activity (Kussie et al., 1996) . The RING finger domain has ubiquitin ligase activity that can mediate MDM2 auto-ubiquitination and p53 ubiquitination, and also provides binding sites for MDMX (Honda and Yasuda, 2000) . Previous studies found that the central region interacts with a variety of regulatory factors such as transcription coactivator p300 (Grossman et al., 1998) , the tumor suppressor Arf (Bothner et al., 2001 ), retinoblastoma protein (Rb) (Sdek et al., 2004) , and fourteen Ribosomal proteins (RPs) (L5, L11, L23, L26, L37, S3, S7, S14, S15, S20, S25, S26, S27, and S27L) (Kim et al., 2014; Sherr, 2006; Zhang and Lu, 2009) (Figure 1 ).
Ribosomal proteins are responsible for the translation of genetic information from mRNA to protein in all living cells. They are anti-neoplastic targets because cancer usurped those proteins. Moreover, they also play key roles in the regulation of p53 via binding to MDM2. Earlier studies suggested that ribosomal stress can affect the integrity of the nucleolus, resulting in the release of RPs into the nucleoplasm where they bind MDM2 and inhibit its activity (Miliani de Marval and Zhang, 2011; Zhang and Lu, 2009). Upon binding to MDM2, the RPs suppress MDM2 E3 ubiquitin ligase activity resulting in the stabilization and activation of p53. Since more than 14 different RP species have been shown to interact with MDM2, why so many RPs bind MDM2 and modulate p53? The reason needs to be elucidated. For all the above RPs, the MDM2 binding region has been mapped to the central region (Kim et al., 2014) . However, how these so different RPs precisely interact with MDM2 remains to be elucidated. Among the reported RPs, RPL11 had the most significant role in p53 activation and ribosomal stress sensing (Fumagalli et played pivotal role in p53 activation in response to ribosomal stress in tumor suppression in mouse models and human tumors. We solved the first structure of the human MDM2 290-334 -RPL11 1-178 complex at 2.4 Å (Zheng et al., 2015) . We identified an unanticipated zinc finger formed inter-molecularly within the complex and found an imidazole molecule chelated in it ( Figure 2 ). This small molecule imidazole might be a promising start of drug design to enhance the binding between MDM2 and RPL11. MDM2 extensively interacts with RPL11 through an acidic domain and two zinc fingers. Formation of the MDM2-RPL11 complex induces substantial conformational changes in both proteins. Mutagenesis studies showed that both acidic region and C4 zinc finger domain were required to establish the MDM2-RPL11 interaction in vitro and in vivo. The C4 zinc finger domain determines the specificity of RPL11 binding to MDM2, but not its homologue MDMX. Overall, this highlights the essential role of the MDM2-RPL11 interaction in p53 activation and tumor suppression, and provides a structural basis for potential new anti-tumor drug development. Interestingly, most MDM2-binding RPs share a conserved feature in that they bind to the central acidic domain of MDM2 (Figure 1 ). Most RPs are very basic proteins, might thus bind MDM2 acidic domain through electrostatic interaction. Unfortunately, MDM2-binding RPs lack obvious similarities in amino acid sequences or three-dimensional structures (Nakao et al., 2004; Yoshihama et al., 2002) . It is unclear whether the molecular mechanism governing the inhibition of MDM2 by RPL11 also applies to other RPs. The structural basis and interaction regions of the MDM2-RPs except RPL11 remain poorly understood. Further structural and functional analysis are needed to uncover the mechanism of these key Ribosomal proteins.
For other non-RPs MDM2-interacting proteins, the structures and mechanisms are still unclear. For example, inactivation of tumor suppressor Rb leads to the development of human malignancies. It was found that MDM2 specifically bound to Rb C-pocket and that the central acidic domain of MDM2 was essential for Rb interaction (Sdek et al., 2004) . In addition, the expression of the wild type MDM2, but not mutant MDM2 defective in Rb interaction, stimulated E2F transactivation activity and inhibited Rb growth suppression function. In vivo, most of the endogenous MDM2 binds p300 and the interaction of p53/MDM2 complex with p300 plays important roles in the MDM2-directed turnover of p53 (Grossman et al., 1998) . Thus, the central acidic domain of MDM2 serves as a specific binding site for both p53 and p300 in vivo, controlling p53 stability and turnover by transcription coactivators such as p300. The medical importance of the Arf-MDM2-p53 regulatory system is highlighted by the finding that either p53 or Arf are lost or modified in virtually all human cancers using surface plasmon resonance and circular dichroism. In response to hyperproliferative signals, Arf stabilizes p53 by binding to the central acidic domain of MDM2 and inhibits the ubiquitination and subsequent degradation of p53. However, the question how MDM2 bind these non-RPs proteins specifically is still unclear. Structural and mutational analysis would be needed.
Secondary structure predicts that most of the acidic domain of MDM2 are disorder. However, the structure might change dramatically after binding interacting proteins. For example, although free Arf and MDM2 domains are disordered in solution, domains of both Arf and MDM2 undergo a great transition from disordered conformations to extended structures comprised of β-strands upon binding. The novel molecular mechanism of interaction and the limited size of the protein domains involved provide opportunities for the development of anticancer therapeutics. For drug design, the RPL11-MDM2 complex structure yield useful anticancer strategies and the unexpected small molecule imidazole might provide a good clue. More structural and small molecules screening would be required to experimentally test the effects in anti-cancer activity.
